Literature DB >> 16310900

Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.

Sharad Kumar Sharma1, Anuradha Dube, Ahmad Nadeem, Shazia Khan, Iram Saleem, Ravendra Garg, Owais Mohammad.   

Abstract

Leishmania donovani promastigote soluble antigens (sLAg) were encapsulated in non-phosphatidylcholine (non-PC) liposomes (escheriosomes) prepared from E. coli lipids. The escheriosome-based vaccine was investigated for its potential to elicit a protective immune response against experimental visceral leishmaniasis. The vaccine administration induced strong humoral as well as cell mediated immune responses both in hamsters and BALB/c mice. Immunization of BALB/c mice with escheriosome entrapped sLAg (EL-sLAg) elicited stronger CD8+ cytotoxic T lymphocyte (CTL) response as compared to sLAg entrapped in egg PC/chol liposome (EPC-sLAg) or sLAg administered with incomplete Freund's adjuvant (IFA-sLAg). EL-sLAg also induced the release of mixed (Th1 and Th2) types of cytokines in the immunized BALB/c mice. In addition, the delivery of sLAg via escheriosomes enhanced the expression of costimulatory signals (CD80 and CD86) as determined in peritoneal macrophages obtained from BALB/c mice. In another set of experiments, the EL-sLAg immunized hamsters were found to be better protected than those immunized with EPC-sLAg. The prophylaxis coincided with increased lymphocyte proliferation as well as high nitric oxide (NO) production by peritoneal macrophages among EL-sLAg immunized hamsters. Escheriosomes thus seem to have potential in delivering the antigen to cytosol of the antigen presenting cells (APCs) and in the development of liposome-based vaccine against leishmaniasis as well as other intracellular infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310900     DOI: 10.1016/j.vaccine.2005.10.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.

Authors:  Takehisa Hebishima; Eiji Yuba; Kenji Kono; Shin-Nosuke Takeshima; Yoshihiro Ito; Yoko Aida
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

Review 2.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

3.  Heat shock proteins enriched-promastigotes of Leishmania major inducing Th2 immune response in BALB/c mice.

Authors:  Marzieh Holakuyee; Mehdi Mahdavi; Zuhair Mohammad Hassan; Mohsen Abolhassani
Journal:  Iran Biomed J       Date:  2012

4.  Leishmania mexicana Gp63 cDNA Using Gene Gun Induced Higher Immunity to L. mexicana Infection Compared to Soluble Leishmania Antigen in BALB/C.

Authors:  H Rezvan; R Rees; Sa Ali
Journal:  Iran J Parasitol       Date:  2011-12       Impact factor: 1.012

5.  Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice.

Authors:  Omid Chavoshian; Nazanin Biari; Ali Badiee; Ali Khamesipour; Azam Abbasi; Zahra Saberi; Seyed Amir Jalali; Mahmoud Reza Jaafari
Journal:  Iran J Basic Med Sci       Date:  2013-09       Impact factor: 2.699

Review 6.  Vaccines to prevent leishmaniasis.

Authors:  Rajiv Kumar; Christian Engwerda
Journal:  Clin Transl Immunology       Date:  2014-03-14

7.  Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery.

Authors:  Dinesh Kumar; Deepak Sharma; Gurmeet Singh; Mankaran Singh; Mahendra Singh Rathore
Journal:  ISRN Pharm       Date:  2012-07-19

8.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

Review 9.  Oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status.

Authors:  Naoya Kojima; Mariko Ishii; Yoko Kawauchi; Hideaki Takagi
Journal:  Biomed Res Int       Date:  2013-10-10       Impact factor: 3.411

10.  Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis.

Authors:  Maritsa Margaroni; Maria Agallou; Evita Athanasiou; Olga Kammona; Costas Kiparissides; Catherine Gaitanaki; Evdokia Karagouni
Journal:  Int J Nanomedicine       Date:  2017-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.